[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2196024T3 - Vacunas conjugadas de gangliosido-klh con qs-21. - Google Patents

Vacunas conjugadas de gangliosido-klh con qs-21.

Info

Publication number
ES2196024T3
ES2196024T3 ES94907279T ES94907279T ES2196024T3 ES 2196024 T3 ES2196024 T3 ES 2196024T3 ES 94907279 T ES94907279 T ES 94907279T ES 94907279 T ES94907279 T ES 94907279T ES 2196024 T3 ES2196024 T3 ES 2196024T3
Authority
ES
Spain
Prior art keywords
vaccine
gangliosido
klh
ganglioside
intensify
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94907279T
Other languages
English (en)
Inventor
Philip O Livingston
Friedhelm Helling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Application granted granted Critical
Publication of ES2196024T3 publication Critical patent/ES2196024T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

EL INVENTO PROPORCIONA UNA VACUNA PARA ESTIMULAR O INTENSIFICAR LA PRODUCCION DE UN ANTICUERPO QUE RECONOCE UNA GANGLIOSIDO EN UN SUJETO AL QUE LE ES ADMINISTRADA LA VACUNA. LA VACUNA ESTA COMPUESTA DE UNA CANTIDAD DE GANGLIOSIDO O PORCION OLIGOSACARIDA DE LA MISMA CONJUGADA CON UNA PROTEINA INMUNOGENICA EFICAZ PARA ESTIMULAR O INTENSIFICAR LA PRODUCCION DE ANTICUERPOS EN EL SUJETO. LA VACUNA ESTA ADEMAS COMPUESTA DE UN VEHICULO ADYUVANTE Y FARMACEUTICAMENTE ACEPTABLE. EL INVENTO TAMBIEN PROPORCIONA UN METODO DE USO DE LA VACUNA PARA EL TRATAMIENTO O PREVENCION DE CANCER EN EL QUE LOS GANGLIOSIDOS ESTAN EN LA SUPERFICIE O EN EL ESTROMA DE LAS CELULAS CANCERIGENAS.
ES94907279T 1993-01-22 1994-01-21 Vacunas conjugadas de gangliosido-klh con qs-21. Expired - Lifetime ES2196024T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US926893A 1993-01-22 1993-01-22

Publications (1)

Publication Number Publication Date
ES2196024T3 true ES2196024T3 (es) 2003-12-16

Family

ID=21736616

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94907279T Expired - Lifetime ES2196024T3 (es) 1993-01-22 1994-01-21 Vacunas conjugadas de gangliosido-klh con qs-21.

Country Status (16)

Country Link
US (6) US7014856B1 (es)
EP (2) EP0680338B1 (es)
JP (1) JP3852945B2 (es)
KR (1) KR100307289B1 (es)
AT (2) ATE372783T1 (es)
AU (1) AU685776B2 (es)
CA (1) CA2154488C (es)
DE (2) DE69435025D1 (es)
DK (1) DK0680338T3 (es)
ES (1) ES2196024T3 (es)
FI (1) FI117668B (es)
HK (1) HK1014659A1 (es)
HU (1) HU221420B1 (es)
NO (1) NO318920B1 (es)
NZ (2) NZ314058A (es)
WO (1) WO1994016731A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2154488C (en) * 1993-01-22 2009-10-13 Philip O. Livingston Ganglioside-klh conjugate vaccines with qs-21
CU22420A1 (es) * 1993-12-29 1996-01-31 Centro Inmunologia Molecular Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US5935821A (en) * 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
AU2735397A (en) * 1996-04-22 1997-11-12 Wistar Institute Of Anatomy And Biology, The Gd2 anti-idiotypic antibodies and uses thereof
US6491919B2 (en) * 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
WO1999015201A1 (en) * 1997-09-25 1999-04-01 Sloan-Kettering Institute For Cancer Research Fucosyl gm1-klh conjugate vaccine against small cell lung cancer
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
EP1903114A3 (en) 1997-12-01 2008-07-23 Neose Technologies, Inc. Enzymatic synthesis of gangliosides
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DE60127113T2 (de) 2000-04-25 2007-06-14 Otsuka Pharmaceutical Co., Ltd. Gd3-mimetische peptide
EP1731161B1 (en) * 2000-12-22 2014-08-06 Lpath, Inc. Sphingosine-1-phosphate antibodies for the treatment of diseases associated with elevated sphingolipid concentrations
WO2003055514A1 (en) 2001-12-21 2003-07-10 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
JP2007501888A (ja) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド ポリシアル酸誘導体
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
EP1838348B1 (en) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanized amyloid beta antibodies for use in improving cognition
CA2593191A1 (en) * 2005-01-14 2006-07-20 Avax Technologies, Inc. Method for producing a vaccine for the treatment of cancer
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US9217749B2 (en) * 2006-05-31 2015-12-22 Lpath, Inc. Immune-derived moieties reactive against lysophosphatidic acid
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2182983B1 (en) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009124294A2 (en) * 2008-04-05 2009-10-08 Lpath, Inc. Pharmaceutical compositions for binding sphingosine-1-phosphate
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8512939B2 (en) * 2009-09-25 2013-08-20 Taiwan Semiconductor Manufacturing Company, Ltd. Photoresist stripping technique
WO2012081508A1 (ja) * 2010-12-13 2012-06-21 日本ケミカルリサーチ株式会社 スフィンゴ糖脂質の定量法
CN106414472A (zh) * 2013-12-06 2017-02-15 现实制药有限公司 用于靶向癌症和产生抗体的抗神经节苷脂化合物
ES2863074T3 (es) 2014-06-04 2021-10-08 Biontech Res And Development Inc Anticuerpos monoclonales humanos contra el gangliósido GD2
US11786586B2 (en) 2016-12-23 2023-10-17 Aoa Dx Carbohydrate structures and uses thereof
MX2020005480A (es) * 2017-12-01 2020-12-07 Glaxosmithkline Biologicals Sa Extraccion de saponina.
CA3142300A1 (en) * 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
WO2023212741A1 (en) * 2022-04-29 2023-11-02 Seneb Biosciences, Inc. Treatment of gm1 deficiencies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4591552A (en) * 1982-09-29 1986-05-27 New York Blood Center, Inc. Detection of hepatitis B surface antigen (or antibody to same) with labeled synthetic peptide
US4557931A (en) * 1982-12-02 1985-12-10 Regents Of The University Of California Antigenic compositions and methods for using same
US4652629A (en) * 1985-07-03 1987-03-24 The Salk Institute For Biological Studies Synthetic peptide-based anti-rabies compositions and methods
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5344870A (en) * 1987-12-02 1994-09-06 Alberta Research Council Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5102663A (en) * 1988-10-18 1992-04-07 Sloan-Kettering Instutute For Cancer Research Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3
DE3840044A1 (de) 1988-11-27 1990-06-07 Behringwerke Ag Glykosphingolipide mit kopplungsfaehiger gruppe im sphingoidanteil, ihre herstellung und verwendung
GB9001694D0 (en) * 1990-01-25 1990-03-28 Therapeutic Antibodies Inc Immunogenic compositions
CA2154488C (en) * 1993-01-22 2009-10-13 Philip O. Livingston Ganglioside-klh conjugate vaccines with qs-21
EP0766741A4 (en) 1994-07-07 1998-02-25 Immunex Corp GM-CSF CONTAINED FUSION PROTEINS AND ANTIGENS AND THEIR EXPRESSION IN YEAST

Also Published As

Publication number Publication date
FI953529A0 (fi) 1995-07-21
EP1360963B1 (en) 2007-09-12
US6967022B1 (en) 2005-11-22
NO952914D0 (no) 1995-07-21
HUT72193A (en) 1996-03-28
HK1014659A1 (en) 1999-09-30
US6936253B1 (en) 2005-08-30
NZ314058A (en) 2000-08-25
JP3852945B2 (ja) 2006-12-06
US7001601B1 (en) 2006-02-21
NO318920B1 (no) 2005-05-23
ATE237357T1 (de) 2003-05-15
EP0680338B1 (en) 2003-04-16
EP1360963A2 (en) 2003-11-12
DE69432513T2 (de) 2003-12-24
CA2154488C (en) 2009-10-13
DE69435025D1 (de) 2007-10-25
FI953529A (fi) 1995-09-15
HU9502201D0 (en) 1995-09-28
JPH08508978A (ja) 1996-09-24
ATE372783T1 (de) 2007-09-15
EP1360963A3 (en) 2003-12-03
US7014856B1 (en) 2006-03-21
HU221420B1 (en) 2002-09-28
AU685776B2 (en) 1998-01-29
NZ261744A (en) 1997-03-24
KR100307289B1 (ko) 2001-12-28
CA2154488A1 (en) 1994-08-04
WO1994016731A1 (en) 1994-08-04
DK0680338T3 (da) 2003-07-21
EP0680338A4 (en) 1997-04-09
NO952914L (no) 1995-09-14
DE69432513D1 (de) 2003-05-22
US20060153859A1 (en) 2006-07-13
FI117668B (fi) 2007-01-15
KR960700073A (ko) 1996-01-19
US6916476B1 (en) 2005-07-12
EP0680338A1 (en) 1995-11-08
AU6092494A (en) 1994-08-15

Similar Documents

Publication Publication Date Title
ES2196024T3 (es) Vacunas conjugadas de gangliosido-klh con qs-21.
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
EA199800946A1 (ru) Концентрированный препарат антител
ES2164251T3 (es) Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre.
ES2157447T3 (es) Composicion de vacuna que comprende un antigeno de polisacarido conjugado adsorbido en fosfato de aluminio.
ES2134797T3 (es) Peptidos y fragmentos de peptidos terapeuticamente utiles.
CO5280094A1 (es) Un analogo de a o app y una composicion inmunogenica que comprende dicho analogo
FI946173A0 (fi) Menetelmä lääkeaineiden antotehon parantamiseksi muunnettujen saponiinien avulla
DE69014137D1 (de) Immunogenische Zusammensetzungen gegen Gastrin-Peptide.
PT90727A (pt) Processo para a preparacao de uma proteina possuindo um ou mais determinantes imuno-reactivos e/ou antigenicos de um antigenio de superficie eimeria e de vacinas contra a coccidiose que a contem
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
ATE255905T1 (de) Iscom oder iscom-matrix, welche einen gegen die schleimhaut gerichteten wirkstoff und ein antigen enthält
EE9800182A (et) PGE-1 sisaldavad lüofiliseeritud liposoomid kasutamiseks erektsioonihäire ravis
ES2079851T3 (es) Uso de il-4 para mejorar la respuesta inmunitaria frente a inmunogenos en vacunas.
DE58904108D1 (de) Arzneimittel.
ITRM930154A0 (it) Uso di terbinafina per il trattamento terapeutico della pneumocistosi.
ES2158857T3 (es) Vacunas a base de estreptoquinasa.
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.
EP0293333A3 (en) A synthetic nonapeptide of use as an adjuvant
DE69322960D1 (de) Empfängnisverhütender impfstoff
ES2102836T3 (es) El empleo de vacunas antihelminticas en el control de la enfermedad parasitaria asociada con la perdida de la inmunidad natural.
IT8821666A0 (it) Coniugato peptidico immunologicamente attivo utile come vaccino antimalaria e metodo di immunizzazione impiegante lo stesso
IT8847913A0 (it) Uso di enalapril nel trattamento terapeutico delle cefalee essenziali
ITRM940453A1 (it) "uso della proteina p1lsa per la preparazione di un medicamento da utilizzarsi nella terapia di patologie indotte da danni cellulari da